Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2011, Article ID 160326, 14 pages
http://dx.doi.org/10.1155/2011/160326
Research Article

Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway

1Mapi Values, Boston, MA 02114, USA
2Global Health Outcomes, Outcome Research, Merck & Co., Inc., One Merck Drive, P. O. Box 100, WS2E-85, Whitehouse Station, NJ 08889, USA

Received 7 January 2011; Accepted 20 March 2011

Academic Editor: Ruben Burgos-Vargas

Copyright © 2011 Jeroen P. Jansen and Stephanie D. Taylor. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Gossec, D. van der Heijde, A. Melian et al., “Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis,” Annals of the Rheumatic Diseases, vol. 64, no. 11, pp. 1563–1567, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. A. Saraux, F. Guillemin, P. Guggenbuhl et al., “Prevalence of spondyloarthropathies in France: 2001,” Annals of the Rheumatic Diseases, vol. 64, no. 10, pp. 1431–1435, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. Braun, M. Bollow, G. Remlinger et al., “Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors,” Arthritis and Rheumatism, vol. 41, no. 1, pp. 58–67, 1998. View at Google Scholar · View at Scopus
  4. N. Akkoc, M. A. Khan, J. Braun, J. Listing, and J. Sieper, “Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: comment on the article by Braun et al,” Arthritis and Rheumatism, vol. 52, no. 12, pp. 4048–4050, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. Boonen, D. van der Heijde, R. Landewé et al., “Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries,” Annals of the Rheumatic Diseases, vol. 62, no. 8, pp. 732–740, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Kobelt, P. Andlin-Sobocki, S. Brophy, L. Jönsson, A. Calin, and J. Braun, “The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade ®),” Rheumatology, vol. 43, no. 9, pp. 1158–1166, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. Sieper and J. Braun, “New treatment options in ankylosing spondylitis: a role for anti-TNFα therapy,” Annals of the Rheumatic Diseases, vol. 60, no. 3, pp. iii58–iii61, 2001. View at Google Scholar · View at Scopus
  8. J. Braun, T. Pham, J. Sieper et al., “International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 62, no. 9, pp. 817–824, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Zochling, D. van der Heijde, M. Dougados, and J. Braun, “Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 65, no. 4, pp. 423–432, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. Keat, N. Barkham, A. Bhalla et al., “BSR guidelines for prescribing TNF-α blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology,” Rheumatology, vol. 44, no. 7, pp. 939–947, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. D. R. Ramey, D. J. Watson, C. Yu, J. A. Bolognese, S. P. Curtis, and A. S. Reicin, “The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis,” Current Medical Research and Opinion, vol. 21, no. 5, pp. 715–722, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. R. H. Hunt, S. Harper, P. Callegari et al., “Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib,” Alimentary Pharmacology and Therapeutics, vol. 17, no. 2, pp. 201–210, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. R. H. Hunt, S. Harper, D. J. Watson et al., “The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events,” American Journal of Gastroenterology, vol. 98, no. 8, pp. 1725–1733, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. F. E. Silverstein, G. Faich, J. L. Goldstein et al., “Gastrointestinal toxicity with Celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and reumatoid arthritis: the CLASS study: a randomized controlled trial,” Journal of the American Medical Association, vol. 284, no. 10, pp. 1247–1255, 2000. View at Google Scholar
  15. C. P. Cannon, S. P. Curtis, G. A. FitzGerald et al., “Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison,” The Lancet, vol. 368, no. 9549, pp. 1771–1781, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. D. van der Heijde, H. S. B. Baraf, C. Ramos-Remus et al., “Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study,” Arthritis and Rheumatism, vol. 52, no. 4, pp. 1205–1215, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. J. Sieper, T. Klopsch, M. Richter et al., “Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study,” Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. 323–329, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. N. J. Cooper, A. J. Sutton, and K. R. Abrams, “Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section,” Statistical Methods in Medical Research, vol. 11, no. 6, pp. 491–512, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. J. P. Jansen, S. Gaugris, E. H. Choy, A. Ostor, J. T. Nash, and W. Stam, “Cost-effectiveness evaluation of etoricoxib versus celecoxib and non-selective NSAIDs in the treatment of ankylosing spondylitis,” PharmacoEconomics, vol. 28, no. 4, pp. 323–344, 2010. View at Google Scholar
  20. R. M. Ara, A. V. Reynolds, and P. Conway, “The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK,” Rheumatology, vol. 46, no. 8, pp. 1338–1344, 2007. View at Publisher · View at Google Scholar · View at PubMed
  21. G. Lu and A. E. Ades, “Combination of direct and indirect evidence in mixed treatment comparisons,” Statistics in Medicine, vol. 23, no. 20, pp. 3105–3124, 2004. View at Publisher · View at Google Scholar · View at PubMed
  22. J. P. Jansen, B. Crawford, G. Bergman, and W. Stam, “Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons,” Value in Health, vol. 11, no. 5, pp. 956–964, 2008. View at Publisher · View at Google Scholar · View at PubMed
  23. A. Boonen, D. van der Heijde, J. L. Severens et al., “Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 65, no. 2, pp. 201–208, 2006. View at Publisher · View at Google Scholar · View at PubMed
  24. A. L. Taylor, C. Balakrishnan, and A. Calin, “Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis,” Arthritis and Rheumatism, vol. 41, no. 6, pp. 1119–1125, 1998. View at Publisher · View at Google Scholar
  25. L. E. Kristensen, T. Saxne, and P. Geborek, “The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in Southern Sweden,” Arthritis and Rheumatism, vol. 54, no. 2, pp. 600–606, 2006. View at Publisher · View at Google Scholar · View at PubMed
  26. A. Barkhuizen, S. Steinfeld, J. Robbins, C. West, J. Coombs, and S. Zwillich, “Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis,” Journal of Rheumatology, vol. 33, no. 9, pp. 1805–1812, 2006. View at Google Scholar
  27. M. Dougados, J. M. Béhier, I. Jolchine et al., “Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug,” Arthritis and Rheumatism, vol. 44, no. 1, pp. 180–185, 2001. View at Google Scholar
  28. L. Laine, S. P. Curtis, B. Cryer, A. Kaur, and C. P. Cannon, “Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison,” The Lancet, vol. 369, no. 9560, pp. 465–473, 2007. View at Publisher · View at Google Scholar · View at PubMed
  29. A. Moore, C. Phillips, E. Hunsche, J. Pellissier, and S. Crespi, “Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK,” PharmacoEconomics, vol. 22, no. 10, pp. 643–660, 2004. View at Publisher · View at Google Scholar
  30. S. P. Curtis, S. Mukhopadhyay , and D. Ramey, “Cardiovascular safety summary associated with the etoricoxib development program,” Arthritis & Rheumatism, vol. 48, pp. S35–S750, 2003. View at Google Scholar
  31. M. R. Tramèr, R. A. Moore, D. J. M. Reynolds, and H. J. McQuay, “Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use,” Pain, vol. 85, no. 1-2, pp. 169–182, 2000. View at Publisher · View at Google Scholar
  32. Life Tables for WHO Member States, 2008, http://www.who.int/healthinfo/statistics/mortality_life_tables/en/.
  33. D. A. Revicki, “Relationship between health utility and psychometric health status measures,” Medical Care, vol. 30, no. 5, pp. MS274–MS282, 1992. View at Google Scholar
  34. W. B. Stason and M. C. Weinstein, “Allocation of resources to manage hypertension,” The New England Journal of Medicine, vol. 296, no. 13, pp. 732–739, 1977. View at Google Scholar
  35. G. Nichol, P. Kaul, E. Huszti, and J. F. P. Bridges, “Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure,” Annals of Internal Medicine, vol. 141, no. 5, pp. 343–351, 2004. View at Google Scholar
  36. J. B. Wong, R. S. Koff, F. Tine, and S. G. Pauker, “Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen- positive chronic hepatitis B,” Annals of Internal Medicine, vol. 122, no. 9, pp. 664–675, 1995. View at Google Scholar
  37. ISF 2007, “Ministry of Health and Care Services,” http://www.helsedirektoratet.no/vp/multimedia/archive/00014/IS-1439_14578a.pdf.
  38. F. A. Sonnenberg and J. R. Beck, “Markov models in medical decision making: a practical guide,” Medical Decision Making, vol. 13, no. 4, pp. 322–338, 1993. View at Publisher · View at Google Scholar
  39. B. S. Bloom, “Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis,” The American Journal of Medicine, vol. 84, no. 2, pp. 20–24, 1988. View at Google Scholar
  40. A. Maetzel, M. B. Ferraz, and C. Bombardier, “The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs,” Arthritis and Rheumatism, vol. 41, no. 1, pp. 16–25, 1998. View at Publisher · View at Google Scholar
  41. R. Knill-Jones, M. Drummond, H. Kohli, and L. Davies, “Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs,” Postgraduate Medical Journal, vol. 66, no. 778, pp. 639–646, 1990. View at Google Scholar
  42. G. Singh and D. R. Ramey, “NSAID induced gastrointestinal complications: the ARAMIS perspective—1997,” Journal of Rheumatology, vol. 25, supplement 51, pp. 8–16, 1998. View at Google Scholar
  43. G. de Pouvourville, “The economic consequences of NSAID-induced gastropathy: the French context,” Scandinavian Journal of Rheumatology, Supplement, vol. 21, no. 96, pp. 49–53, 1992. View at Google Scholar
  44. B. Jönsson and U. Haglund, “Cost-effectiveness of misoprostol in Sweden,” International Journal of Technology Assessment in Health Care, vol. 8, no. 2, pp. 234–244, 1992. View at Google Scholar
  45. S. E. Gabriel and E. L. Matteson, “Economic and quality-of-life impact of NSAIDs in rheumatoid arthritis. A conceptual framework and selected literature review,” PharmacoEconomics, vol. 8, no. 6, pp. 479–490, 1995. View at Google Scholar
  46. W. E. Smalley, M. R. Griffin, R. L. Fought, and W. A. Ray, “Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs,” Journal of General Internal Medicine, vol. 11, no. 8, pp. 461–469, 1996. View at Google Scholar
  47. J. T. Edelson, A. N. A. Tosteson, and P. Sax, “Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding,” Journal of the American Medical Association, vol. 264, no. 1, pp. 41–47, 1990. View at Publisher · View at Google Scholar
  48. S. E. Gabriel, M. E. Campion, and W. M. O'Fallon, “Patient preferences for nonsteroidal antiinflammatory drug related gastrointestinal complications and their prophylaxis,” Journal of Rheumatology, vol. 20, no. 2, pp. 358–361, 1993. View at Google Scholar
  49. R. E. Johnson, M. C. Hornbrook, R. S. Hooker, G. T. Woodson, and R. Shneidman, “Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation,” PharmacoEconomics, vol. 12, no. 1, pp. 76–88, 1997. View at Google Scholar
  50. S. X. Kong, H. T. Hatoum, S. Z. Zhao, N. M. Agrawal, and S. G. Geis, “Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: comparison of two national databases,” American Journal of Managed Care, vol. 4, no. 3, pp. 399–409, 1998. View at Google Scholar
  51. M. F. Botteman, J. W. Hay, M. P. Luo, A. S. Curry, R. L. Wong, and B. A. van Hout, “Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom,” Rheumatology, vol. 46, no. 8, pp. 1320–1328, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus